300015:SZSEAier Eye Hospital Group Co., Ltd. Class A Analysis

Aier Eye Hospital is trading at CNY 8.28, well below its 20‑day (8.82), 50‑day (9.63) and 200‑day (11.12) moving averages, signalling a bearish technical backdrop. The RSI of 29 suggests the stock is oversold, while a bearish MACD histogram (-0.018) and decreasing volume reinforce short‑term downside pressure toward the nearest support at CNY 8.15. Despite the technical weakness, the DCF‑derived fair value of CNY 5.74 implies the market price is currently overvalued relative to intrinsic estimates, even though the forward PE of 20 is modestly below the industry average of 24.7. Analysts are highly optimistic, with a median target of CNY 14.65—over 70% upside—driven by solid earnings growth and a healthy dividend yield of 2.9%.
Fundamentally, the company posts a respectable 15% ROE, operating margin of 25.7% and profit margin of 14.8%, underpinned by steady 6% revenue growth. Cash generation is strong (operating cash flow CNY 5.86 bn) and the net‑debt position is modest, supporting a 66% payout ratio that appears sustainable. Low systematic risk (beta ≈ 0.1) is offset by high 30‑day volatility (~30%) and medium regulatory exposure in China’s healthcare sector, suggesting a balanced risk‑reward profile for investors.